Clinical Evidence Supporting the Use of Crisaborole in Vitiligo

Abstract

Crisaborole is a topical non-steroidal phosphodiesterase-4 (PDE4) inhibitor that has gained increasing attention in dermatology due to its anti-inflammatory and immunomodulatory properties. It was first approved for the treatment of mild to moderate atopic dermatitis, where it reduces inflammatory cytokine production through elevation of intracellular cyclic adenosine monophosphate (cAMP). Beyond its approved indication, emerging evidence suggests potential therapeutic roles for crisaborole in several dermatologic conditions, including psoriasis, seborrheic dermatitis, contact dermatitis, and vitiligo. Recent studies have highlighted its favorable safety profile, minimal systemic absorption, and suitability for long-term topical use, particularly in sensitive skin areas. Additionally, inhibition of PDE4 may modulate inflammatory pathways and promote melanocyte survival and melanogenesis, providing a theoretical basis for its use in vitiligo management. This mini-review summarizes the pharmacology, mechanism of action, clinical applications, and emerging evidence regarding the role of crisaborole in dermatologic diseases, with particular emphasis on its potential role in vitiligo.